Phase 1 trial finds triple monoclonal antibody combination safe and effective for HIV-1 prevention
By
Dr Sharana Mahomed, MD PhDa Send email to [email protected]
Summary
This phase 1, multicentre, randomised, open-label trial (HVTN 140/HPTN 101 part B) evaluated the safety, pharmacokinetics, and neutralisation activity of a combination of three broadly neutralising monoclonal antibodies (PGDM1400LS, VRC07-523LS, and PGT121.414.LS) targeting different HIV-1 epitopes, administered intravenously or subcutaneously in healthy adults without HIV-1 across sites in the USA, Kenya, South Africa, and Zimbabwe. The mAb combination was found to be safe and well tolerated, with no antagonistic pharmacokinetic interactions or loss of neutralisation activity, supporting further evaluation in future efficacy trials for HIV-1 prevention.
Source
bskyPhase 1 trial finds triple monoclonal antibody combination safe and effective for HIV-1 preventionthelancet.comKey quotes
· 3 pulledPassive immunisation with a combination of broadly neutralising monoclonal antibodies (mAbs) presents a potential HIV-1 prevention modality.
The mAb combination of PGDM1400LS, PGT121.414.LS, and VRC07-523LS was safe and well tolerated, with no antagonistic pharmacokinetic interactions or loss of neutralisation activity.
These findings support further evaluation of this combination in future efficacy trials.
You might also wanna read
Challenges and approaches in developing an HIV vaccine through broadly neutralizing antibodies
This article discusses the challenges and potential approaches to developing an effective HIV vaccine. It highlights that while therapies ex
scim.ag·8d ago
PARTNERS trial begins enrolling patients in DRC to test treatments for Bundibugyo virus disease
The PARTNERS clinical trial has begun enrolling patients in the Democratic Republic of the Congo to evaluate potential treatments for Bundib
who.int·2d agoPARTNERS trial begins enrolling patients in DRC to test treatments for Bundibugyo virus disease
The PARTNERS clinical trial has begun enrolling patients in the Democratic Republic of the Congo to evaluate potential treatments for Bundib
who.int·2d ago
FDA Approves First 100% Effective HIV Prevention Drug with Global Impact
The article discusses the milestone approval of the first HIV prevention drug, lenacapavir (brand name Yeztugo), which offers 100% protectio
newatlas.com·11mo agoEnhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies
New plasma proteomics model improves thrombosis risk prediction in cancer patients and identifies IL-17-driven endothelial activation as therapeutic target
This article presents research by Karagkouni and colleagues who developed a new cancer-associated venous thromboembolism (VTE) prediction mo
scim.ag·11d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.